Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)

Covid19 Clinical Trial

Official title: Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)

Status Withdrawn

Clinical Trial Summary

The current research is a pilot study to determine the feasibility of recruiting and retaining 40 participants diagnosed with COVID-19. The purpose is to observe the early use of fluoxetine (commonly known as Prozac) to reduce the severity of the COVID-19 illness. Fluoxetine is a drug that has been approved by the U.S. Food and Drug Administration (FDA) since 1987 for various mental health disorders.

Clinical Trial Description

Morbidity and mortality resulting from COVID-19 infections are associated with multisystem organ failure due to a rapid increase in cytokine production. Fluoxetine has been shown to reduce the mechanisms that cause the cytokine storm that leads to COVID-19 fatalities. This is a pilot study to assess feasibility of recruiting and retaining participants diagnosed with COVID-19. The purpose of this study is to observe the early use of fluoxetine treatments on illness outcome: primary outcome is hospitalization and secondary outcomes of complications including intubation and death. Additional secondary outcomes include effects on outcomes for depression and post-traumatic stress disorder, two common illnesses which may be improved by fluoxetine. ;

Related Conditions & MeSH terms

• Covid19
• Infection

• NCT number: NCT04570449
• Study type: Interventional
• Source: Milton S. Hershey Medical Center
• Status: Withdrawn
• Phase: Early Phase 1
• Start date: November 2020
• Completion date: December 2021